Insider Selling: Emergent Biosolutions (NYSE:EBS) Director Sells 13,761 Shares of Stock

Emergent Biosolutions Inc. (NYSE:EBS) Director Sujata Tyagi Dayal sold 13,761 shares of the firm’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $8.40, for a total transaction of $115,592.40. Following the transaction, the director owned 100,563 shares of the company’s stock, valued at approximately $844,729.20. This represents a 12.04% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Emergent Biosolutions Price Performance

EBS traded up $0.04 during midday trading on Monday, reaching $8.51. 839,196 shares of the company’s stock were exchanged, compared to its average volume of 878,575. The firm has a market capitalization of $439.23 million, a price-to-earnings ratio of -30.38 and a beta of 2.33. The company has a quick ratio of 2.08, a current ratio of 4.29 and a debt-to-equity ratio of 1.10. Emergent Biosolutions Inc. has a one year low of $4.71 and a one year high of $14.06. The business has a 50-day simple moving average of $8.54 and a two-hundred day simple moving average of $10.30.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $0.21 EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.46. The firm had revenue of $156.10 million during the quarter, compared to analysts’ expectations of $145.00 million. Emergent Biosolutions had a negative net margin of 1.27% and a positive return on equity of 10.76%.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. Weiss Ratings lowered shares of Emergent Biosolutions from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, April 27th. Wall Street Zen lowered shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. Finally, HC Wainwright lowered their target price on shares of Emergent Biosolutions from $15.00 to $12.00 and set a “buy” rating on the stock in a report on Monday, March 9th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Emergent Biosolutions presently has a consensus rating of “Hold” and a consensus target price of $12.00.

Institutional Investors Weigh In On Emergent Biosolutions

A number of hedge funds have recently added to or reduced their stakes in the stock. Values First Advisors Inc. grew its holdings in Emergent Biosolutions by 0.9% during the 1st quarter. Values First Advisors Inc. now owns 307,880 shares of the biopharmaceutical company’s stock worth $2,555,000 after acquiring an additional 2,834 shares during the last quarter. SG Americas Securities LLC boosted its stake in shares of Emergent Biosolutions by 4.6% in the 1st quarter. SG Americas Securities LLC now owns 42,394 shares of the biopharmaceutical company’s stock valued at $352,000 after purchasing an additional 1,865 shares during the last quarter. Evolve Private Wealth LLC bought a new position in shares of Emergent Biosolutions in the 1st quarter valued at about $546,000. Baron Wealth Management LLC boosted its stake in shares of Emergent Biosolutions by 40.2% in the 1st quarter. Baron Wealth Management LLC now owns 15,120 shares of the biopharmaceutical company’s stock valued at $125,000 after purchasing an additional 4,335 shares during the last quarter. Finally, Zacks Investment Management bought a new position in shares of Emergent Biosolutions in the 4th quarter valued at about $141,000. Institutional investors own 78.40% of the company’s stock.

Emergent Biosolutions Company Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.